Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493866 | 0.86 | CNR2 (0.39) | CNR2TRPV3CTSSCTSKCNR1 | |
| SCHEMBL22480829 | 0.85 | TRPV3 (0.43) | TRPV3CTSSCTSKCTSLCTSB | |
| SCHEMBL22493472 | 0.84 | TRPV3 (0.43) | CNR2TRPV3CTSSCTSKCNR1 | |
| SCHEMBL22480758 | 0.79 | TRPV3 (0.39) | TRPV3CTSSCTSKCTSLCTSB | |
| SCHEMBL22493739 | 0.79 | PDE10A (0.49) | TRPV3CTSSCTSKCTSLCTSB | |
| SCHEMBL18014812 | 0.79 | CNR2 (0.46) | CNR2TRPV3CTSSCTSKCNR1 | |
| SCHEMBL22493434 | 0.78 | CYP2A6 (0.50) | TRPV3ABL1 | |
| SCHEMBL22493894 | 0.78 | SCN9A (0.44) | TRPV3CTSSCTSKCTSLCTSB | |
| SCHEMBL22493438 | 0.77 | CNR2 (0.43) | CNR2SHMT1 | |
| SCHEMBL22493399 | 0.76 | CYP3A4 (0.36) | CTSSCTSKCTSLCTSBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137506-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023225021-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2020198466-A9 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020198466-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |